ÂÜÀòÂÒÂ×

Alexander Chu-Kung is the head of development at Adcentrx Therapeutics. Prior to joining Adcentrx, Dr Chu-Kung was the Senior Director of Development at Levena Biopharma, a subsidiary of Sorrento Therapeutics where he was responsible for all aspects of process development, cGMP manufacturing and clinical supply of the antibody drug conjugate pipeline.

Before joining Levena Biopharma, Dr Chu-Kung spent more than decade at Abbvie, most recently as a principal scientist. In this role he oversaw process development, tech transfer, CMO interaction and scale-up for both small molecule and biologic therapeutics.

Alexander holds a Ph.D. degree in Chemical Engineering from University of California, Santa Barbara and a B.S. degree in chemical engineering from Northwestern University.